{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:39:52Z","timestamp":1791333592180,"version":"4.3.1"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Labor Berlin"},{"DOI":"10.13039\/501100013865","name":"Charit\u00e9 Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Ministry of Education and Research"},{"name":"German Ministry of Health"},{"name":"German Innovations Funds"},{"DOI":"10.13039\/501100021727","name":"Berlin University Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021727","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Institute of the Statutory Health Insurance Physicians"},{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Care Research"},{"name":"German Ministry of Education and Research"},{"name":"German Ministry of Health"},{"name":"German Innovations Funds"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neutralizing autoantibodies against type I interferons are a risk factor for multiple severe viral diseases. The timely detection of these autoantibodies remains an unmet need. We hypothesized that paradoxically low expression of type I IFN-induced CD169\/SIGLEC1 expression analyzed by flow cytometry may allow rapid screening for the presence of these autoantibodies. In a prospective cohort study, we quantified monocytic CD169\/SIGLEC1 expression and neutralizing autoantibodies against type I interferons in 808 patients who presented to the emergency room with signs of acute infections during the second wave of the SARS-CoV-2 pandemic in Germany in 2021. In patients, elevated CD169\/SIGLEC1 (&amp;gt;2400 mAb\/cell) demonstrated a negative predictive value of 100% for the detection of neutralizing autoantibodies against type I interferons. Low CD169\/SIGLEC1 (&amp;lt;2400 mAb\/cell) and a CRP &amp;gt;50 mg\/L exhibited a positive predictive value of 70% for neutralizing autoantibodies against type I interferons. We further compared the adjusted odds ratio for mortality in patients with these autoantibodies to that in patients without autoantibodies against type I interferons. Neutralizing autoantibodies against type I interferons were associated with a worse clinical outcome, independent of SARS-CoV-2 infection, implying their presence is a risk factor for a worse general outcome.<\/jats:p>","DOI":"10.1093\/cei\/uxaf074","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T12:54:12Z","timestamp":1764680052000},"source":"Crossref","is-referenced-by-count":2,"title":["Autoantibodies against type I interferons correlate with low CD169\/SIGLEC1 and severe non-viral infections in ER patients"],"prefix":"10.1093","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5825-8838","authenticated-orcid":false,"given":"Olga","family":"Staudacher","sequence":"first","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health , Berlin ,","place":["Germany"]},{"name":"Department of Immunology, Labor Berlin Charit\u00e9-Vivantes , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7942-6448","authenticated-orcid":false,"given":"Tim","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Immunology, Labor Berlin Charit\u00e9-Vivantes , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1263-4313","authenticated-orcid":false,"given":"Bengisu","family":"Akbil","sequence":"additional","affiliation":[{"name":"Institute of Virology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5118-3324","authenticated-orcid":false,"given":"Miriam","family":"Mayer","sequence":"additional","affiliation":[{"name":"Emergency and Acute Medicine, Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Schmoll","sequence":"additional","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health , Berlin ,","place":["Germany"]},{"name":"Department of Immunology, Labor Berlin Charit\u00e9-Vivantes , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5052-5049","authenticated-orcid":false,"given":"Uwe","family":"K\u00f6lsch","sequence":"additional","affiliation":[{"name":"Department of Immunology, IMD Berlin Potsdam GbR , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Unterwalder","sequence":"additional","affiliation":[{"name":"Department of Immunology, Labor Berlin Charit\u00e9-Vivantes , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2608-0347","authenticated-orcid":false,"given":"Anna","family":"Slagman","sequence":"additional","affiliation":[{"name":"Emergency and Acute Medicine, Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0222-991X","authenticated-orcid":false,"given":"Christian","family":"Meisel","sequence":"additional","affiliation":[{"name":"Department of Immunology, Labor Berlin Charit\u00e9-Vivantes , Berlin ,","place":["Germany"]},{"name":"Institute of Medical Immunology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-004X","authenticated-orcid":false,"given":"Christine","family":"Goffinet","sequence":"additional","affiliation":[{"name":"Institute of Virology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin ,","place":["Germany"]},{"name":"Berlin Institute of Health (BIH) at Charit\u00e9 - Universit\u00e4tsmedizin \u00a0 Berlin, Berlin ,","place":["Germany"]},{"name":"Department of Tropical Disease Biology, Liverpool School of Tropical Medicine , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7691-3709","authenticated-orcid":false,"given":"Martin","family":"M\u00f6ckel","sequence":"additional","affiliation":[{"name":"Emergency and Acute Medicine, Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5812-7675","authenticated-orcid":false,"given":"Horst","family":"von Bernuth","sequence":"additional","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health , Berlin ,","place":["Germany"]},{"name":"Department of Immunology, Labor Berlin Charit\u00e9-Vivantes , Berlin ,","place":["Germany"]},{"name":"Berlin Institute of Health (BIH) at Charit\u00e9 - Universit\u00e4tsmedizin \u00a0 Berlin, Berlin ,","place":["Germany"]},{"name":"Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu \u00a0 Berlin, Berlin ,","place":["Germany"]},{"name":"Berlin Institute of Health (BIH) , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"2026041706070170800_uxaf074-B1","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41564-019-0421-x","article-title":"Decoding type I and III interferon signalling during viral infection","volume":"4","author":"Mesev","year":"2019","journal-title":"Nat Microbiol"},{"key":"2026041706070170800_uxaf074-B2","doi-asserted-by":"crossref","first-page":"e00985","DOI":"10.1128\/JVI.00985-20","article-title":"Type I and type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures","volume":"94","author":"Vanderheiden","year":"2020","journal-title":"J Virol"},{"key":"2026041706070170800_uxaf074-B3","doi-asserted-by":"crossref","first-page":"e20220514","DOI":"10.1084\/jem.20220514","article-title":"Autoantibodies against type I IFNs in patients with critical influenza pneumonia","volume":"219","author":"Zhang","year":"2022","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B4","doi-asserted-by":"crossref","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"2026041706070170800_uxaf074-B5","doi-asserted-by":"crossref","first-page":"eabl4340","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in \u223c4% of uninfected individuals over 70 years old and account for \u223c20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci Immunol"},{"key":"2026041706070170800_uxaf074-B6","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10875-022-01252-2","article-title":"Early and rapid identification of COVID-19 patients with neutralizing type I interferon auto-antibodies","volume":"42","author":"Akbil","year":"2022","journal-title":"J Clin Immunol"},{"key":"2026041706070170800_uxaf074-B7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10875-024-01683-z","article-title":"Prevalence of neutralizing autoantibodies against type I interferon in a multicenter cohort of severe or critical COVID-19 cases in Shanghai","volume":"44","author":"Shi","year":"2024","journal-title":"J Clin Immunol"},{"key":"2026041706070170800_uxaf074-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.129.1.1","article-title":"Antibodies to alpha-interferon in a patient with systemic lupus erythematosus","volume":"129","author":"Panem","year":"1982","journal-title":"J Immunol"},{"key":"2026041706070170800_uxaf074-B9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1600-0625.1996.tb00119.x","article-title":"High-titer interferon-\u03b1 antibodies in a patient with Pemphigus foliaceus","volume":"5","author":"Pr\u00fcmmer","year":"1996","journal-title":"Exp Dermatol"},{"key":"2026041706070170800_uxaf074-B10","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0140-6736(05)64012-3","article-title":"Spontaneous neutralising antibodies to interferon-a and interleukin-12 in thymoma-associated autoimmune disease","volume":"350","author":"Meager","year":"1997","journal-title":"Lancet"},{"key":"2026041706070170800_uxaf074-B11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-2249.2003.02113.x","article-title":"Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and\/or myasthenia gravis","volume":"132","author":"Meager","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"2026041706070170800_uxaf074-B12","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1172\/JCI80477","article-title":"Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency","volume":"125","author":"Walter","year":"2015","journal-title":"J Clin Invest"},{"key":"2026041706070170800_uxaf074-B13","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/art.39607","article-title":"Distinct functions of anti-interferon autoantibodies in systemic lupus erythematosus: a comprehensive analysis of anticytokine autoantibodies in common rheumatologic diseases","volume":"68","author":"Gupta","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026041706070170800_uxaf074-B14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.clim.2017.09.011","article-title":"Severe toxoplasma gondii infection in a member of a NFKB2-deficient family with T and B cell dysfunction","volume":"183","author":"Maccari","year":"2017","journal-title":"Clin Immunol"},{"key":"2026041706070170800_uxaf074-B15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3389\/fimmu.2018.00544","article-title":"Neutralizing anti-cytokine autoantibodies against interferon-\u03b1 in immunodysregulation polyendocrinopathy enteropathy X-linked","volume":"9","author":"Rosenberg","year":"2018","journal-title":"Front Immunol"},{"key":"2026041706070170800_uxaf074-B16","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/0961203320935976","article-title":"Characterization of type-I IFN subtype autoantibodies and activity in SLE serum and urine","volume":"29","author":"Harris","year":"2020","journal-title":"Lupus"},{"key":"2026041706070170800_uxaf074-B17","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1182\/blood.2021014890","article-title":"Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms","volume":"139","author":"Borsani","year":"2022","journal-title":"Blood"},{"key":"2026041706070170800_uxaf074-B18","doi-asserted-by":"crossref","first-page":"e20240365","DOI":"10.1084\/jem.20240365","article-title":"Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies","volume":"221","author":"Fernbach","year":"2024","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cei\/uxad119","article-title":"Type 1 interferon auto-antibodies are elevated in patients with decompensated liver cirrhosis","volume":"215","author":"Greville","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"2026041706070170800_uxaf074-B20","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41586-023-06717-x","article-title":"Autoantibodies against type I IFNs in humans with alternative NF-\u03baB pathway deficiency","volume":"623","author":"Le Voyer","year":"2023","journal-title":"Nature"},{"key":"2026041706070170800_uxaf074-B21","doi-asserted-by":"crossref","first-page":"e20231152","DOI":"10.1084\/jem.20231152","article-title":"Incontinentia pigmenti underlies thymic dysplasia, autoantibodies to type I IFNs, and viral diseases","volume":"221","author":"Rosain","year":"2024","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B22","doi-asserted-by":"crossref","first-page":"e150867","DOI":"10.1172\/JCI150867","article-title":"Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1","volume":"131","author":"Meisel","year":"2021","journal-title":"J Clin Invest"},{"key":"2026041706070170800_uxaf074-B23","doi-asserted-by":"crossref","first-page":"e13116","DOI":"10.1111\/irv.13116","article-title":"Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial","volume":"17","author":"Alotaibi","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"2026041706070170800_uxaf074-B24","doi-asserted-by":"crossref","first-page":"e3001709","DOI":"10.1371\/journal.pbio.3001709","article-title":"Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease","volume":"20","author":"Busnadiego","year":"2022","journal-title":"PLoS Biol"},{"key":"2026041706070170800_uxaf074-B25","doi-asserted-by":"crossref","first-page":"e20230661","DOI":"10.1084\/jem.20230661","article-title":"Autoantibodies neutralizing type I IFNs underlie west Nile virus encephalitis in \u223c40% of patients","volume":"220","author":"Gervais","year":"2023","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B26","doi-asserted-by":"crossref","first-page":"e20240942","DOI":"10.1084\/jem.20240942","article-title":"Auto-abs neutralizing type I IFNs in patients with severe powassan, usutu, or ross river virus disease","volume":"221","author":"Gervais","year":"2024","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B27","doi-asserted-by":"crossref","first-page":"e20240637","DOI":"10.1084\/jem.20240637","article-title":"Autoantibodies neutralizing type I IFNs underlie severe tick-borne encephalitis in \u223c10% of patients","volume":"221","author":"Gervais","year":"2024","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B28","doi-asserted-by":"crossref","first-page":"e20202486","DOI":"10.1084\/jem.20202486","article-title":"Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaci.2021.03.034","article-title":"Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis","volume":"148","author":"Lemarquis","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026041706070170800_uxaf074-B30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10875-021-01023-5","article-title":"Interferon-\u03b2 therapy in a patient with Incontinentia Pigmenti and autoantibodies against type I IFNs infected with SARS-CoV-2","volume":"41","author":"Bastard","year":"2021","journal-title":"J Clin Immunol"},{"key":"2026041706070170800_uxaf074-B31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41598-022-25930-8","article-title":"Impact of plasmapheresis on severe COVID-19","volume":"13","author":"Fonseca-Gonz\u00e1lez","year":"2023","journal-title":"Sci Rep"},{"key":"2026041706070170800_uxaf074-B32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cytogfr.2021.03.006","article-title":"COVID-19 as a mediator of interferon deficiency and hyperinflammation: rationale for the use of JAK1\/2 inhibitors in combination with interferon","volume":"60","author":"Hasselbalch","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"2026041706070170800_uxaf074-B33","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1126\/science.abc2061","article-title":"Type I and III interferons disrupt lung epithelial repair during recovery from viral infection","volume":"369","author":"Major","year":"2020","journal-title":"Science"},{"key":"2026041706070170800_uxaf074-B34","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1177\/0961203320965699","article-title":"SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus","volume":"29","author":"von Stuckrad","year":"2020","journal-title":"Lupus"},{"key":"2026041706070170800_uxaf074-B35","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s10875-021-01141-0","article-title":"Intrinsic defects in B cell development and differentiation, T cell exhaustion and altered unconventional T cell generation characterize human adenosine deaminase type 2 deficiency","volume":"41","author":"Yap","year":"2021","journal-title":"J Clin Immunol"},{"key":"2026041706070170800_uxaf074-B36","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/infdis\/jiaa724","article-title":"Monocyte CD169 expression as a biomarker in the early diagnosis of coronavirus disease 2019","volume":"223","author":"Bedin","year":"2021","journal-title":"J Infect Dis"},{"key":"2026041706070170800_uxaf074-B37","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s15010-021-01606-9","article-title":"CD169\/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity","volume":"49","author":"Doehn","year":"2021","journal-title":"Infection"},{"key":"2026041706070170800_uxaf074-B38","doi-asserted-by":"crossref","first-page":"e20210554","DOI":"10.1084\/jem.20210554","article-title":"Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B39","doi-asserted-by":"crossref","first-page":"m1328","DOI":"10.1136\/bmj.m1328","article-title":"Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal","volume":"369","author":"Wynants","year":"2020","journal-title":"BMJ"},{"key":"2026041706070170800_uxaf074-B40","first-page":"e0223","article-title":"Treatment of critically ill coronavirus disease 2019 patients with adjunct therapeutic plasma exchange: a single-center retrospective case series","volume":"2","author":"Keith","year":"2020","journal-title":"Crit Care Explor"},{"key":"2026041706070170800_uxaf074-B41","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1126\/science.aaa1578","article-title":"Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency","volume":"348","author":"Ciancanelli","year":"2015","journal-title":"Science"},{"key":"2026041706070170800_uxaf074-B42","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1084\/jem.20180628","article-title":"Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency","volume":"215","author":"Hernandez","year":"2018","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B43","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1084\/jem.20181621","article-title":"Severe influenza pneumonitis in children with inherited TLR3 deficiency","volume":"216","author":"Lim","year":"2019","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B44","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/eji.201848083","article-title":"Identification of an IRF3 variant and defective antiviral interferon responses in a patient with severe influenza","volume":"49","author":"Thomsen","year":"2019","journal-title":"Eur J Immunol"},{"key":"2026041706070170800_uxaf074-B45","doi-asserted-by":"crossref","first-page":"e1003951","DOI":"10.1371\/journal.ppat.1003951","article-title":"Induction of type I interferon signaling determines the relative pathogenicity of Staphylococcus aureus strains","volume":"10","author":"Parker","year":"2014","journal-title":"PLoS Pathog"},{"key":"2026041706070170800_uxaf074-B46","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/ng1097","article-title":"Impaired response to interferon-alpha\/beta and lethal viral disease in human STAT1 deficiency","volume":"33","author":"Dupuis","year":"2003","journal-title":"Nat Genet"},{"key":"2026041706070170800_uxaf074-B47","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1126\/science.1128346","article-title":"Herpes simplex virus encephalitis in human UNC-93B deficiency","volume":"314","author":"Casrouge","year":"2006","journal-title":"Science"},{"key":"2026041706070170800_uxaf074-B48","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1371\/journal.pgen.0020131","article-title":"Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease","volume":"2","author":"Chapgier","year":"2006","journal-title":"PLoS Genet"},{"key":"2026041706070170800_uxaf074-B49","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1126\/science.1139522","article-title":"TLR3 deficiency in patients with herpes simplex encephalitis","volume":"317","author":"Zhang","year":"2007","journal-title":"Science"},{"key":"2026041706070170800_uxaf074-B50","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.immuni.2010.08.014","article-title":"Human TRAF3 adaptor molecule deficiency leads to impaired toll-like receptor 3 response and susceptibility to herpes simplex encephalitis","volume":"33","author":"de Diego","year":"2010","journal-title":"Immunity"},{"key":"2026041706070170800_uxaf074-B51","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jaci.2011.04.059","article-title":"NEMO is a key component of NF-\u03baB- and IRF-3-dependent TLR3-mediated immunity to herpes simplex virus","volume":"128","author":"Audry","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"2026041706070170800_uxaf074-B52","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1084\/jem.20101568","article-title":"Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity","volume":"208","author":"Guo","year":"2011","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-010-9480-8","article-title":"Novel STAT1 alleles in a patient with impaired resistance to mycobacteria","volume":"31","author":"Kristensen","year":"2011","journal-title":"J Clin Immunol"},{"key":"2026041706070170800_uxaf074-B54","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1172\/JCI59259","article-title":"Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency","volume":"121","author":"Sancho-Shimizu","year":"2011","journal-title":"J Clin Invest"},{"key":"2026041706070170800_uxaf074-B55","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1084\/jem.20111316","article-title":"Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood","volume":"209","author":"Herman","year":"2012","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B56","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1073\/pnas.1220098110","article-title":"STAT2 deficiency and susceptibility to viral illness in humans","volume":"110","author":"Hambleton","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026041706070170800_uxaf074-B57","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1084\/jem.20142274","article-title":"Functional IRF3 deficiency in a patient with herpes simplex encephalitis","volume":"212","author":"Andersen","year":"2015","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B58","doi-asserted-by":"crossref","first-page":"307ra154","DOI":"10.1126\/scitranslmed.aac4227","article-title":"Human IFNAR2 deficiency: lessons for antiviral immunity","volume":"7","author":"Duncan","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026041706070170800_uxaf074-B59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clim.2016.11.004","article-title":"A heterozygous dominant-negative mutation in the coiled-coil domain of STAT1 is the cause of autosomal-dominant Mendelian susceptibility to mycobacterial diseases","volume":"174","author":"Ueki","year":"2017","journal-title":"Clinical Immunology"},{"key":"2026041706070170800_uxaf074-B60","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1084\/jem.20182295","article-title":"Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines","volume":"216","author":"Hernandez","year":"2019","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B61","doi-asserted-by":"crossref","first-page":"e139980","DOI":"10.1172\/JCI139980","article-title":"Herpes simplex encephalitis in a patient with a distinctive form of inherited IFNAR1 deficiency","volume":"131","author":"Bastard","year":"2021","journal-title":"J Clin Invest"},{"key":"2026041706070170800_uxaf074-B62","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s10875-020-00907-2","article-title":"Pathogenic TLR3 variant in a patient with recurrent herpes Simplex virus 1\u2013triggered erythema Multiforme","volume":"41","author":"Bucciol","year":"2021","journal-title":"J Clin Immunol"},{"key":"2026041706070170800_uxaf074-B63","doi-asserted-by":"crossref","first-page":"e20211349","DOI":"10.1084\/jem.20211349","article-title":"Inborn errors of TLR3- or MDA5-dependent type I IFN immunity in children with enterovirus rhombencephalitis","volume":"218","author":"Chen","year":"2021","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B64","doi-asserted-by":"crossref","first-page":"e20220202","DOI":"10.1084\/jem.20220202","article-title":"Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency","volume":"219","author":"Campbell","year":"2022","journal-title":"J Exp Med"},{"key":"2026041706070170800_uxaf074-B65","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s10875-022-01339-w","article-title":"Genetic and functional identifying of novel STAT1 loss-of-function mutations in patients with diverse clinical phenotypes","volume":"42","author":"Chen","year":"2022","journal-title":"J Clin Immunol"},{"key":"2026041706070170800_uxaf074-B66","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbrc.2021.11.036","article-title":"Two novel STAT1 mutations cause Mendelian susceptibility to mycobacterial disease","volume":"591","author":"Liu","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"2026041706070170800_uxaf074-B67","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s10875-021-01170-9","article-title":"Life-threatening enterovirus 71 encephalitis in unrelated children with autosomal dominant TLR3 deficiency","volume":"42","author":"Kuo","year":"2022","journal-title":"J Clin Immunol"},{"key":"2026041706070170800_uxaf074-B68","doi-asserted-by":"crossref","first-page":"1002140","DOI":"10.3389\/fcimb.2022.1002140","article-title":"A novel STAT1 loss-of-function mutation associated with Mendelian susceptibility to mycobacterial disease","volume":"12","author":"Ye","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2026041706070170800_uxaf074-B69","doi-asserted-by":"crossref","first-page":"e154016","DOI":"10.1172\/JCI154016","article-title":"IRF7 and UNC93B1 variants in an infant with recurrent herpes simplex virus infection","volume":"133","author":"Tucker","year":"2023","journal-title":"J Clin Invest"},{"key":"2026041706070170800_uxaf074-B70","doi-asserted-by":"crossref","first-page":"e1001109","DOI":"10.1371\/journal.ppat.1001109","article-title":"Pathogen specific, IRF3-dependent signaling and innate resistance to human kidney infection","volume":"6","author":"Fischer","year":"2010","journal-title":"PLoS Pathog"},{"key":"2026041706070170800_uxaf074-B71","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12931-022-02283-4","article-title":"Prevalence of type-1 interferon autoantibodies in adults with non-COVID-19 acute respiratory failure","volume":"23","author":"Ghale","year":"2022","journal-title":"Respir Res"},{"key":"2026041706070170800_uxaf074-B72","first-page":"173","article-title":"Spatio-temporal trends in the incidence of type 2 diabetes in Germany","volume":"120","author":"T\u00f6nnies","year":"2023","journal-title":"Dtsch Arztebl Int"},{"key":"2026041706070170800_uxaf074-B73","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12963-016-0111-3","article-title":"Monitoring the prevalence of thyroid disorders in the adult population of northeast Germany","volume":"14","author":"Khattak","year":"2016","journal-title":"Popul Health Metr"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxaf074\/65672633\/uxaf074.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/220\/1\/uxaf074\/68104330\/uxaf074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/220\/1\/uxaf074\/68104330\/uxaf074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:07:22Z","timestamp":1776420442000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/doi\/10.1093\/cei\/uxaf074\/8362827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxaf074","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2025,12,2]]},"article-number":"uxaf074"}}